#USA #Menlo Park #Mayo Clinic #Phenomix #MyPhenome

New Insights into Precision Obesity Medicine Presented at ObesityWeek 2026

During the recent ObesityWeek 2026, a prominent medical conference focused on obesity and its treatment, groundbreaking research was showcased by Phenomix Sciences in collaboration with the Mayo Clinic. This research focuses on understanding how genetics and individual clinical characteristics can impact patient responses to GLP-1 medications, such as semaglutide and tirzepatide.

Dr. Andres Acosta, M.D., Ph.D., a co-founder of Phenomix and physician scientist at Mayo Clinic, led this extensive research effort. Importantly, three separate studies were presented, further validating the efficacy of the MyPhenome® test in tailoring obesity treatment to individual patients.

Key Findings from the Studies

One of the highlights of this research is a comprehensive study involving over 45,000 patients that investigates weight regain post-treatment. The findings revealed a remarkable variance in how long it took different patients to regain weight after discontinuing GLP-1 medications. Notably, high-risk patients might regain half of their lost weight in as little as two months, while low-risk individuals could take up to 19 months to do the same. This study introduced a predictive model that assesses patients' risk levels based on their genetic and clinical profiles.

Statistical Outcomes

• - On average, participants experienced a weight loss of about 11.3% with semaglutide and 11.0% with tirzepatide.
• - After stopping these medications, participants regained an average of 73.7% and 69.2% of the weight they had lost, respectively.
• - Those identified as high-risk regained half their lost weight in merely 1.8 months and 2.0 months following semaglutide and tirzepatide cessation, contrasting sharply with the 19.0 and 19.2 months for the low-risk group.

The study suggests that factors such as a greater initial weight loss and longer treatment duration correlate with a delayed onset of weight regain. Remarkably, patients who had lost over 20% of their initial body weight retained a net loss of approximately 13% and 16% for semaglutide and tirzepatide, respectively, even two years after treatment.

The Role of MyPhenome® Test

Furthermore, the research underscored the potential of the MyPhenome® genetic test in identifying patients likely to benefit from GLP-1 medications. This test, a simple cheek swab, analyzes vital biological factors contributing to obesity. One study revealed that patients categorized under the “Hungry Gut” genetic profile lost an average of 17.0% of their weight at the one-year mark when treated with tirzepatide, significantly outperforming the average loss of 13.9% observed in other participants.

Another study aimed at enhancing the predictive capabilities of the MyPhenome test showed that integrating it with clinical data could foresee patient responses to semaglutide before any treatment began. Patients in the top predictive category lost an average of 18.3% of their weight at 12 months, while those in the intermediate and low groups showed lesser average losses.

Broader Implications for Obesity Treatment

Dr. Acosta emphasized that traditionally, obesity treatment often overlooks individual patient differences. Through these research findings, the ability to personalize obesity care by tailoring treatments based on genetic markers and clinical indicators appears crucial for achieving better patient outcomes. “Precision medicine should be part of everyday obesity care,” Dr. Acosta remarked, highlighting the necessity for healthcare practitioners to adopt a more individualized approach.

Moreover, with nearly 400 healthcare clinics currently employing the MyPhenome test and its availability online for patients, Phenomix aims to revolutionize how obesity treatment is approached across the healthcare landscape. The company has also partnered with Proto360 Health, a metabolic care platform, to integrate the MyPhenome test into their comprehensive patient care programs.

In conclusion, the studies presented at ObesityWeek 2026 advance our understanding of obesity treatment, stressing the importance of personalized medicine in enhancing therapeutic outcomes for patients. As more research unfolds, the collaboration between biotechnology and clinical practices promises to reshape the future of obesity management, making it more effective and personalized than ever before.